Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss

Back to Jobs

OTO -413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing tests A single intratympanic injection of OTO -413 was well-tolerated Otonomy intends to continue clinical development of OTO -413 Management will review results during a conference call

Apply Now